{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:35:19Z","timestamp":1775093719622,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ajem.2016.12.070","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T13:52:44Z","timestamp":1483624364000},"page":"502-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anticoagulants in ischemia-guided management of non-ST-elevation acute coronary syndromes"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-2274","authenticated-orcid":false,"given":"Martin","family":"Mayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.ajem.2016.12.070_bb0005","first-page":"e344","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.ajem.2016.12.070_bb0010","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ajem.2016.12.070_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/ebmed-2015-110275","article-title":"Elucidating the use of enoxaparin in non-ST-elevation acute coronary syndromes (NSTE-ACS)","volume":"21","author":"Mayer","year":"2016","journal-title":"Evid Based Med"},{"key":"10.1016\/j.ajem.2016.12.070_bb0020","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-Wave Coronary Events Study Group","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2016.12.070_bb0025","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2016.12.070_bb0030","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1067\/mhj.2002.126115","volume":"144","author":"Cohen","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.ajem.2016.12.070_bb0035","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/01.CIR.0000050144.67910.13","volume":"107","author":"Goodman","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2016.12.070_bb0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jama.292.1.55","article-title":"\u2018A to Z\u2019 investigators. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial","volume":"292","author":"Blazing","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ajem.2016.12.070_bb0045","first-page":"45","article-title":"SYNERGY trial investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"Ferguson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ajem.2016.12.070_bb0050","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/01.CIR.100.15.1602","article-title":"Assessment of the treatment effect of enoxaparin for unstable angina\/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.ajem.2016.12.070_bb0055","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1001\/jama.289.19.2554","article-title":"Composite outcomes in randomized trials: greater precision but with greater uncertainty?","volume":"289","author":"Freemantle","year":"2003","journal-title":"JAMA"},{"issue":"7491","key":"10.1016\/j.ajem.2016.12.070_bb0060","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/bmj.330.7491.594","article-title":"Validity of composite end points in clinical trials","volume":"330","author":"Montori","year":"2005","journal-title":"BMJ"},{"issue":"7597","key":"10.1016\/j.ajem.2016.12.070_bb0065","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/bmj.39136.682083.AE","article-title":"Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials","volume":"334","author":"Ferreira-Gonz\u00e1lez","year":"2007","journal-title":"BMJ"},{"issue":"7597","key":"10.1016\/j.ajem.2016.12.070_bb0070","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/bmj.39176.461227.80","article-title":"Composite and surrogate outcomes in randomised controlled trials","volume":"334","author":"Freemantle","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.ajem.2016.12.070_bb0075","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-121-3-199408010-00008","article-title":"The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results","volume":"121","author":"Goodman","year":"1994","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ajem.2016.12.070_bb0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1198\/000313001300339897","article-title":"The abuse of power: the pervasive fallacy of power calculations for data analysis","volume":"55","author":"Hoenig","year":"2001","journal-title":"Am Stat"},{"issue":"9467","key":"10.1016\/j.ajem.2016.12.070_bb0085","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0140-6736(05)61034-3","article-title":"Sample size calculations in randomised trials: mandatory and mystical","volume":"365","author":"Schulz","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ajem.2016.12.070_bb0090","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/euhj.2001.2779","article-title":"TIMI 11B and ESSENCE investigators. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE","volume":"23","author":"Antman","year":"2002","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.ajem.2016.12.070_bb0095","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ajem.2016.12.070_bb0100","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"CURRENT-OASIS 7 investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ajem.2016.12.070_bb0105","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"PLATO investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ajem.2016.12.070_bb0110","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"TRITON-TIMI 38 investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ajem.2016.12.070_bb0115","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ajem.2016.12.070_bb0120","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.ajem.2016.12.070_bb0125","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajem.2016.12.070_bb0130","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajem.2016.12.070_bb0135","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.294.20.2594","article-title":"SYNERGY trial investigators. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6months and 1year in the SYNERGY trial","volume":"294","author":"Mahaffey","year":"2005","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.ajem.2016.12.070_bb0140","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2016.12.070_bb0145","article-title":"Heparin versus placebo for non-ST elevation acute coronary syndromes","volume":"6","author":"Andrade-Castellanos","year":"2014","journal-title":"Cochrane Database Syst Rev"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675716309925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675716309925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:34:45Z","timestamp":1760024085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675716309925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0735675716309925"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2016.12.070","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulants in ischemia-guided management of non-ST-elevation acute coronary syndromes","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2016.12.070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}